ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TRX Tissue Regenix Group Plc

62.50
-0.50 (-0.79%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.79% 62.50 62.00 63.00 62.50 62.50 62.50 2,827 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 24.48M -2.7M -0.0382 -16.36 44.11M

Tissue Regenix Group PLC Issue of Equity (1940A)

22/12/2017 9:30am

UK Regulatory


Tissue Regenix (LSE:TRX)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Tissue Regenix Charts.

TIDMTRX

RNS Number : 1940A

Tissue Regenix Group PLC

22 December 2017

Tissue Regenix Group Plc

Issue of equity and total voting rights

Leeds, 22 December 2017 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company, announces that it has today issued and allotted 8,307,608 ordinary shares of 0.5p each in the Company, following an exercise of options which were granted in respect of a 2010 EMI award.

The 8,307,608 new ordinary shares will rank pari passu with the existing ordinary shares and application has been made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00a.m. on Friday 29 December 2017.

Total Voting Rights

Following the issue of the 8,307,608 new ordinary shares, the Company will have a total of ordinary 1,170,990,924 ordinary shares of 0.5p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For more Information:

 
 Tissue Regenix Group plc                   Tel: 0330 
  Steve Couldwell CEO                        430 3073 
  Caitlin Pearson Head of Communications     / 07920272441 
========================================  ================ 
 Jefferies International Ltd               Tel: 020 
  Simon Hardy / Chris Binks                 7029 8000 
 FTI Consulting                            Tel: 0203 
  Brett Pollard/ Mo Noonan / Rob Winder     727 1000 
========================================  ================ 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEKLLBLDLFBFBE

(END) Dow Jones Newswires

December 22, 2017 04:30 ET (09:30 GMT)

1 Year Tissue Regenix Chart

1 Year Tissue Regenix Chart

1 Month Tissue Regenix Chart

1 Month Tissue Regenix Chart

Your Recent History

Delayed Upgrade Clock